17.40 -0.07 (-0.40%)
After hours: 6:06PM EST
|Bid||17.44 x 1800|
|Ask||17.48 x 2900|
|Day's range||17.06 - 17.50|
|52-week range||12.43 - 20.00|
|Beta (5Y monthly)||1.11|
|PE ratio (TTM)||21.53|
|Forward dividend & yield||0.85 (4.80%)|
|Ex-dividend date||29 Sep 2020|
|1y target est||N/A|
Merck (MRK) is stepping up to help Johnson & Johnson (JNJ) produce its COVID-19 vaccine, which was authorized last weekend.
Moderna's (MRNA) partner Takeda doses the first participant in a phase I/II study with Moderna's coronavirus vaccine candidate, mRNA-1273 in Japan.
Coronavirus stock Moderna (NASDAQ: MRNA) was up by nearly 8% in mid-afternoon trading on Thursday. Two pieces of news about the company's coronavirus vaccine seem to be supporting this rise. The first is Moderna's announcement that dosing of participants has begun in a phase 1/2 clinical trial for mRNA-1273 in Japan.